Differential Transcriptomic Landscapes of SARS-CoV-2 Variants in Multiple Organs from Infected Rhesus Macaques DOI Creative Commons
Tingfu Du, Chun‐Chun Gao, Shuaiyao Lu

и другие.

Genomics Proteomics & Bioinformatics, Год журнала: 2023, Номер 21(5), С. 1014 - 1029

Опубликована: Июль 13, 2023

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the persistent disease 2019 (COVID-19) pandemic, which has resulted in millions of deaths worldwide and brought an enormous public health global economic burden. The recurring wave infections been exacerbated by growing variants SARS-CoV-2. In this study, virological characteristics original SARS-CoV-2 strain its concern (VOCs; including Alpha, Beta, Delta) vitro, as well differential transcriptomic landscapes multiple organs (lung, right ventricle, blood, cerebral cortex, cerebellum) from infected rhesus macaques, were elucidated. a stronger innate immune response host cells, VOCs markedly increased levels subgenomic RNA s, such N, Orf9b, Orf6, Orf7ab, are known antagonists inhibitors antiviral factors. Intriguingly, Alpha variant induced larger alteration abundance tissues monkeys than Beta Delta did. Moreover, hyperinflammatory state active shown ventricles up-regulation inflammation- immune-related RNAs. Furthermore, peripheral blood may mediate signaling transmission among to coordinate molecular changes individuals. Collectively, these data provide insights into pathogenesis COVID-19 at early stage infection VOCs.

Язык: Английский

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants DOI Creative Commons
Divya Teli, Pankti C. Balar, Kishan Patel

и другие.

Metabolites, Год журнала: 2023, Номер 13(2), С. 309 - 309

Опубликована: Фев. 20, 2023

The nucleoside analog β-D-N4-hydroxycytidine is the active metabolite of prodrug molnupiravir and accepted as an efficient drug against COVID-19. Molnupiravir targets RNA-dependent RNA polymerase (RdRp) enzyme, which responsible for replicating viral genome during replication process certain types viruses. It works by disrupting normal function RdRp causing it to make mistakes genome. These can prevent from being transcribed, converted into a complementary DNA template, translated, or functional protein. By these crucial steps in process, effectively inhibit virus reduce its ability cause disease. This review article sheds light on impact SARS-CoV-2 variants concern, such delta, omicron, hybrid/recombinant variants. detailed mechanism molecular interactions using docking dynamics have also been covered. safety tolerability patients with comorbidities emphasized.

Язык: Английский

Процитировано

29
Fucoidan from Ascophyllum nodosum and Undaria pinnatifida attenuate SARS-CoV-2 infection in vitro and in vivo by suppressing ACE2 and alleviating inflammation DOI

Fang‐Shu Shi,

Yv-Hao Xie,

Yong‐Le Yang

и другие.

Carbohydrate Polymers, Год журнала: 2024, Номер 332, С. 121884 - 121884

Опубликована: Янв. 29, 2024

Язык: Английский

Процитировано

12
Erythronecroptosis: an overview of necroptosis or programmed necrosis in red blood cells DOI
Anton Tkachenko, Ondřej Havránek

Molecular and Cellular Biochemistry, Год журнала: 2024, Номер 479(12), С. 3273 - 3291

Опубликована: Март 1, 2024

Язык: Английский

Процитировано

10
Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial DOI Open Access

Lidong Gao,

Yan Li, Peng He

и другие.

The Lancet Child & Adolescent Health, Год журнала: 2023, Номер 7(4), С. 269 - 279

Опубликована: Фев. 17, 2023

Язык: Английский

Процитировано

17
Global Distribution, Dispersal Patterns, and Trend of Several Omicron Subvariants of SARS-CoV-2 across the Globe DOI Creative Commons
Ioannis Kopsidas, Sofia Karagiannidou, Evangelia Georgia Kostaki

и другие.

Tropical Medicine and Infectious Disease, Год журнала: 2022, Номер 7(11), С. 373 - 373

Опубликована: Ноя. 12, 2022

Our study aims to describe the global distribution and dispersal patterns of SARS-CoV-2 Omicron subvariants. Genomic surveillance data were extracted from CoV-Spectrum platform, searching for BA.1*, BA.2*, BA.3*, BA.4*, BA.5* variants by geographic region. BA.1* increased in November 2021 South Africa, with a similar increase across all continents early December 2021. did not reach 100% dominance continents. The spread first described differed greatly region, contrast which followed expansion, firstly occurring Asia subsequently Europe, Oceania, North America. BA.4* different pattern, where reached high proportions (maximum 60%) only Africa. is currently, Mid-August 2022, dominant strain, reaching almost continent aside Africa show increasing proportions, Asia, Americas, Oceania are following. emergence new depends mostly on their selective advantage, translated as enhanced transmissibility ability invade people existing immunity. Describing these useful better understanding epidemiology VOCs' transmission generating hypotheses about future emerging variants.

Язык: Английский

Процитировано

25
Changes in symptoms and characteristics of COVID-19 patients across different variants: two years study using neural network analysis DOI Creative Commons

Seyed Hossein Torabi,

Seyed Mohammad Riahi, Azadeh Ebrahimzadeh

и другие.

BMC Infectious Diseases, Год журнала: 2023, Номер 23(1)

Опубликована: Ноя. 28, 2023

Considering the fact that COVID-19 has undergone various changes over time, its symptoms have also varied. The aim of this study is to describe and compare in personal characteristics, symptoms, underlying conditions individuals infected with different strains COVID-19.This descriptive-analytical was conducted on 46,747 patients who underwent PCR testing during a two-year period from February 22, 2020 23, 2022, South Khorasan province, Iran. Patient characteristics were extracted based self-report information system. data analyzed using logistic regression artificial neural network approaches. R software used for analysis significance level 0.05 considered tests.Among cases analyzed, 23,239 (49.7%) male, mean age 51.48 ± 21.41 years. There significant difference among variants disease (p < 0.001). factors positive association myalgia (OR: 2.04; 95% CI, 1.76 - 2.36), cough 1.93; 1.68-2.22), taste or smell disorder 2.62; 2.1 3.28). Additionally, aging found increase likelihood across six periods.We older age, myalgia, taste/smell are better compared dyspnea high body temperature, identifying patient. As evolved, chills diarrhea, demonstrated prognostic strength as Omicron.

Язык: Английский

Процитировано

16
Antiphospholipid syndrome in the era of COVID-19 – Two sides of a coin DOI
Naim Mahroum,

Mona Habra,

Mohamad Aosama Alrifaai

и другие.

Autoimmunity Reviews, Год журнала: 2024, Номер 23(9), С. 103543 - 103543

Опубликована: Апрель 9, 2024

Язык: Английский

Процитировано

5
Computational modeling and prediction of deletion mutants DOI Open Access
Hope Woods, Dominic L. Schiano,

Jonathan I. Aguirre

и другие.

Structure, Год журнала: 2023, Номер 31(6), С. 713 - 723.e3

Опубликована: Апрель 28, 2023

Язык: Английский

Процитировано

11
Accelerating SARS-CoV-2 genomic surveillance in a routine clinical setting with nanopore sequencing DOI Creative Commons
Sergio Buenestado‐Serrano,

Marta Herránz,

Álvaro Otero

и другие.

International Journal of Medical Microbiology, Год журнала: 2024, Номер 314, С. 151599 - 151599

Опубликована: Янв. 18, 2024

SARS-CoV-2 genomic analysis has been key to the provision of valuable data meet both epidemiological and clinical demands. High-throughput sequencing, generally Illumina-based, necessary ensure widest coverage in global variant tracking. However, a speedier response is needed for nosocomial outbreak analyses rapid identification patients infected by emerging VOCs. An alternative based on nanopore sequencing may be better suited delivering faster when required; however, although there are several studies offering side-by-side comparisons Illumina evaluations usefulness hospital routine availability provided still lacking. We performed prospective 10-week nanopore-based MinION laboratory setting, including 83 specimens where time was necessary. The analyzed corresponded i) international travellers which lineages were assigned determine proper management/special isolation patients; ii) infections health-care-worker infections, SNP-based required rule in/out relationships tailor specific interventions iii) sentinel cases breakthrough timely report Public Health authorities. MinION-based compared with standard procedures, supported sequencing; accelerated delivery results (average 30 h) reduced costs 28€ Illumina, without reducing accuracy SNP calling. Parallel integration strategies suitable solution high-throughput cope accelerating surveillance demands while also maintaining accuracy.

Язык: Английский

Процитировано

4
Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors DOI Creative Commons

Rominah Onintsoa Diarimalala,

Yanhong Wei,

Da Hu

и другие.

Frontiers in Cellular and Infection Microbiology, Год журнала: 2023, Номер 13

Опубликована: Июнь 9, 2023

Corona Virus Disease 2019 (COVID-19) continues to be a burden for human health since its outbreak in Wuhan, China December 2019. Recently, the emergence of new variants concerns (VOCs) is challenging vaccines and drugs efficiency. In severe cases, SARS-CoV-2 provokes inappropriate hyperinflammatory immune responses leading acute respiratory distress syndrome (ARDS) even death. This process regulated by inflammasomes which are activated after binding viral spike (S) protein cellular angiotensin-converting enzyme 2 (ACE2) receptor triggers innate responses. Therefore, formation “cytokines storm” leads tissue damage organ failure. NOD-like family pyrin domain containing 3 (NLRP3) best studied inflammasome known during infection. However, some studies suggest that infection associated with other as well; such NLRP1, absent melanoma-2 (AIM-2), caspase-4 -8 were mostly found dsRNA virus or bacteria Multiple inhibitors exist non-infectious diseases have potential used treat complications. Some them showed quite encouraging results pre- clinical trials. Nevertheless, further need understanding targeting SARS-Cov-2-induced inflammasomes; an update role VOCs necessary. Hence, this review highlights all reported involved their including NLRP3- Gasdermin D (GSDMD)-inhibitors. Further strategies immunomodulators siRNA also discussed. As highly related COVID-19 developing holds promise effectively reduce mortality.

Язык: Английский

Процитировано

10